Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.

13.05 0.15 +1.16%
Market cap
$10.7B
P/E
32.9×
Fwd P/E
24.3×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
Piotroski F-Score
4 2 6 8 6 5 7 8 5 5
P/E ratio
25.79 19.98 18.30 17.10 29.88 43.04 24.60 25.19 35.22 36.83
Altman Z-Score
5.26 5.94 8.43 7.87 6.38 7.07 6.30 5.35 3.86 4.33
P/S ratio
3.22 2.88 3.67 3.16 3.27 3.93 2.89 3.02 2.46 3.08
Altman Z″-Score (non-manufacturers)
6.10 6.93 8.73 8.51 6.56 6.32 6.70 5.81 4.50 3.84
P/FCF ratio
53.62 69.98 53.50 19.42 56.74 32.12 20.90 20.76 49.30 0.00
P/Operating CF
77.38 42.42 89.82 39.07 80.42 66.55 477.74 67.96 63.22 47.79
Beneish M-Score
(2.59) (1.97) (2.25) (2.68) (2.38) (2.78) (2.56) (2.73) (2.62) (2.46)
Dividend Safety Score
74 — — — — — — — — —
P/B ratio
2.84 2.78 3.66 3.36 3.68 4.30 3.25 3.32 2.76 3.50
Price to Tangible BV
4.12 4.11 4.28 3.97 4.42 5.60 4.09 5.07 4.49 5.76
EV/Sales
3.19 2.85 3.45 2.96 3.21 3.90 2.86 3.11 2.67 3.30
EV/EBITDA
15.04 10.41 11.68 10.43 16.67 16.20 11.04 14.48 16.05 18.76
EV/Operating CF
18.81 19.91 21.22 12.36 24.55 20.71 16.73 16.67 21.03 21.58
EV/FCF
53.09 69.10 50.29 18.18 55.73 31.88 20.70 21.36 53.45 (23.96)
Quick Ratio
1.13 1.14 1.69 1.58 1.20 1.03 1.06 1.09 0.89 0.66
Current Ratio
1.80 1.92 2.58 2.41 1.93 1.78 1.79 1.92 1.57 1.18
Net Debt/EBITDA
(0.15) (0.13) (0.75) (0.71) (0.30) (0.12) (0.10) 0.40 1.25 1.24
Debt/Assets
13.34% 9.48% 5.18% 4.19% 11.55% 11.40% 9.51% 17.03% 22.45% 22.36%
Debt/Equity
0.20 0.14 0.07 0.06 0.18 0.18 0.14 0.27 0.40 0.40
Asset Turnover
0.60 0.73 0.78 0.77 0.75 0.77 0.73 0.66 0.64 0.67
Operating CF/Net income
1.33 0.82 0.82 1.31 1.19 2.07 1.53 1.53 1.83 1.78
Capex/Depreciation
(1.78) (1.94) (1.77) (1.49) (1.33) (0.98) (0.46) (0.52) (0.93) (3.63)
Interest Coverage
13.48 25.52 38.67 40.88 29.92 34.54 33.46 17.76 14.08 17.33
ROE
11.40% 18.13% 21.63% 20.60% 12.76% 10.68% 12.69% 13.70% 7.83% 9.66%
ROA
7.63% 12.72% 15.60% 14.09% 8.30% 7.03% 8.17% 8.09% 4.41% 5.70%
ROIC
8.55% 13.82% 19.31% 19.68% 10.36% 12.25% 13.64% 8.51% 4.78% 5.45%
Return on Tangible Assets
17.09% 26.05% 24.32% 24.00% 15.73% 14.15% 17.78% 17.27% 10.05% 16.64%
Average Days of Receivables
110.01 101.33 104.92 107.60 113.66 95.54 105.12 94.49 104.43 98.69
Research and Development Expense of Revenue
7.15% 8.40% 8.18% 7.89% 8.14% 8.71% 8.81% 10.16% 12.88% 13.86%
Selling, General and Administrative Expense of Revenue
31.76% 28.84% 27.64% 27.67% 28.95% 28.80% 28.71% 31.78% 33.01% 32.93%
Intangible Assets out of Total Assets
0.20 0.22 0.11 0.11 0.11 0.15 0.14 0.21 0.22 0.22
Share Based Compensation of Revenue
0.08% 0.13% 0.15% 0.17% 0.28% 0.31% 0.30% 0.27% 0.32% 0.28%
Graham Net Nets
0.10 0.10 0.14 0.15 0.11 0.07 0.11 0.06 0.03 0.01
Graham Number
7.67 8.39 8.58 7.12 5.04 4.28 4.28 4.21 3.12 3.35
Earnings Yield
3.88% 5.00% 5.46% 5.85% 3.35% 2.32% 4.06% 3.97% 2.84% 2.71%
Free Cash Flow Yield
1.86% 1.43% 1.87% 5.15% 1.76% 3.11% 4.78% 4.82% 2.03% (4.47%)
Revenue per Share
4.30 4.58 4.03 3.60 3.41 3.13 2.79 2.68 2.63 2.61
Operating CF per Share
0.73 0.65 0.66 0.86 0.45 0.59 0.48 0.50 0.33 0.40
Capex per Share
(0.47) (0.47) (0.38) (0.28) (0.25) (0.21) (0.09) (0.11) (0.20) (0.76)
Free Cash Flow per Share
0.26 0.19 0.28 0.59 0.20 0.38 0.39 0.39 0.13 (0.36)
Cash per Share
1.13 0.82 1.18 0.92 0.74 0.59 0.43 0.44 0.39 0.34
Shareholders Equity per Share
4.87 4.74 4.05 3.38 3.03 2.85 2.48 2.44 2.34 2.30
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.87 4.74 4.05 3.38 3.03 2.85 2.48 2.44 2.34 2.30
Free Cash Flow
215.00 157.00 230.00 487.00 163.00 317.00 320.00 324.00 109.00 (299.00)
Working Capital
1,432.00 1,401.00 1,824.00 1,474.00 1,158.00 887.00 763.00 793.00 614.00 237.00
Capital Expenditures
(392.00) (388.00) (315.00) (229.00) (207.00) (171.00) (76.00) (91.00) (168.00) (631.00)
Net Current Asset Value
1,098.00 1,103.00 1,692.00 1,412.00 1,049.00 763.00 704.00 424.00 161.00 71.00
EV/EBIT
21.18 12.88 14.24 12.74 23.35 22.51 15.23 22.91 31.84 34.45
Capex to Sales
0.11 0.10 0.09 0.08 0.07 0.07 0.03 0.04 0.08 0.29
Price to Operating Income
21.39 13.05 15.15 13.61 23.77 22.68 15.38 22.28 29.36 32.17
Other line items
Depreciation/Fixed assets
0.18 0.17 0.19 0.19 0.19 0.22 0.24 0.23 0.20 0.20
Cash ROIC
3.70% 3.03% 5.02% 13.02% 4.57% 9.69% 11.83% 11.00% 3.58% (10.12%)
Accounts Receivable Turnover
3.35 3.77 3.63 3.40 3.63 3.85 3.73 3.71 3.60 3.59
Accounts Payable Turnover
4.38 4.01 4.00 3.93 4.00 4.34 4.96 4.46 4.44 4.90
Inventory Turnover
2.05 1.98 2.05 2.05 2.05 2.18 2.25 2.18 2.28 2.33
Average Days of Payables
76.84 96.27 97.63 90.69 92.83 100.11 75.46 75.29 89.35 78.46
Days of Inventory on Hand
176.13 192.08 200.79 166.73 184.84 191.28 158.77 174.25 161.70 166.77
Average Receivables
1,068.50 1,010.50 922.50 881.00 779.50 673.00 621.50 600.00 605.50 605.00
Average Payables
386.50 394.00 346.50 329.50 331.00 273.00 215.50 228.50 227.00 196.50
Average Inventory
824.00 797.50 677.50 631.50 646.00 543.00 475.50 466.50 443.50 413.00
Average Assets
5,973.50 5,211.00 4,283.00 3,888.00 3,745.00 3,355.50 3,170.00 3,362.00 3,427.50 3,262.00
Average Common Equity
4,000.50 3,656.50 3,088.50 2,660.50 2,438.00 2,210.50 2,040.50 1,985.00 1,928.00 1,925.00

Fold the line items

Columns are period end dates